Recently published data indicate that despite widespread prescribing of low-dose naltrexone to treat fibromyalgia-related pain in women, there is no evidence that the drug has any analgesic effect.
The randomized, double-blind, placebo-controlled trial was onducted at the Pain Center of Odense University Hospital, in Denmark, in women 18 to 64 years of age (mean age, 56 years) (Lancet Rheumatol 2023;6[1]:e31-e39). Researchers screened a total of 158 participants for eligibility from Jan. 6, 2021